Immuneering - Class A Share Price Today

Immuneering enters supply deal with Astellas for pancreatic cancer trials

Immuneering Corp supplies atebimetinib for two Astellas-sponsored pancreatic cancer trials. Studies target patients with CLDN18.2-expressing tumors. Marks Immuneering's fourth agreement with a pharmaceutical partner. One trial tests combination with mGnP; other tests chemotherapy-free regimen.

Immuneering shows 50% regression with atebimetinib in colorectal model

Immuneering Corporation announced preclinical data for atebimetinib at the SITC 2026 meeting. The drug enhanced PD-1 checkpoint blockade activity in RAS-mutant colorectal and lung cancer models. Data showed a 50% durable complete regression rate in a colorectal cancer model. A triple combination therapy yielded a 1.8-fold median survival improvement in a lung model.

Immuneering to present atebimetinib data at SITC annual meeting

Immuneering Corporation will present a poster at the SITC annual meeting in November 2026. Preclinical data shows atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumors. Findings support an upcoming Phase 2 study combining atebimetinib with PD-1 blockade in lung cancer. The lead author for abstract number 377 is Amy E. Axel.

Immuneering highlights atebimetinib potential as FDA approves new 2L treatment

FDA approved a new second-line metastatic pancreatic cancer treatment on August 26, 2026. Immuneering is advancing atebimetinib into a Phase 3 trial for first-line metastatic disease. Phase 2a data showed 17.3-month median overall survival with atebimetinib plus mGnP. 84% of patients maintained or gained weight, addressing cachexia concerns. Grade 3+ adverse events were limited to chemotherapy-related anemia (16%) and neutropenia (18%).

Immuneering reports atebimetinib shows broad preclinical activity

Immuneering Corporation announced the publication of findings in Cancer Research detailing the broad and durable preclinical activity of atebimetinib across RAS- and RAF-mutant tumors. The study highlighted that atebimetinib demonstrated deeper and more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib in head-to-head studies, while maintaining favorable tolerability. Immuneering is currently recruiting patients for a Phase 3 pivotal trial evaluating atebimetinib in first-line metastatic pancreatic cancer.

Needham maintains Buy on Immuneering, raises target to $18

Needham analyst Ami Fadia has maintained a Buy rating on Immuneering and raised the price target to $18 from $11.